nodes	percent_of_prediction	percent_of_DWPC	metapath
Saxagliptin—ABCC1—Vandetanib—thyroid cancer	0.315	0.39	CbGbCtD
Saxagliptin—ABCC1—Epirubicin—thyroid cancer	0.217	0.269	CbGbCtD
Saxagliptin—ABCC1—Doxorubicin—thyroid cancer	0.115	0.143	CbGbCtD
Saxagliptin—CYP3A5—Sorafenib—thyroid cancer	0.0704	0.0872	CbGbCtD
Saxagliptin—CYP3A4—Vandetanib—thyroid cancer	0.0455	0.0564	CbGbCtD
Saxagliptin—CYP3A4—Sorafenib—thyroid cancer	0.0274	0.034	CbGbCtD
Saxagliptin—CYP3A4—Doxorubicin—thyroid cancer	0.0166	0.0206	CbGbCtD
Saxagliptin—DPP8—saliva-secreting gland—thyroid cancer	0.01	0.168	CbGeAlD
Saxagliptin—DPP8—trachea—thyroid cancer	0.00771	0.129	CbGeAlD
Saxagliptin—DPP9—thyroid gland—thyroid cancer	0.0067	0.112	CbGeAlD
Saxagliptin—DPP8—thyroid gland—thyroid cancer	0.0061	0.102	CbGeAlD
Saxagliptin—Lymphopenia—Sorafenib—thyroid cancer	0.00553	0.0414	CcSEcCtD
Saxagliptin—SLCO4C1—trachea—thyroid cancer	0.00488	0.0818	CbGeAlD
Saxagliptin—DPP4—saliva-secreting gland—thyroid cancer	0.0042	0.0704	CbGeAlD
Saxagliptin—DPP9—lymph node—thyroid cancer	0.00416	0.0698	CbGeAlD
Saxagliptin—DPP8—lymph node—thyroid cancer	0.00379	0.0635	CbGeAlD
Saxagliptin—Gastroenteritis—Vandetanib—thyroid cancer	0.00343	0.0257	CcSEcCtD
Saxagliptin—Hypoglycaemia—Vandetanib—thyroid cancer	0.00312	0.0233	CcSEcCtD
Saxagliptin—Blood creatinine increased—Vandetanib—thyroid cancer	0.00285	0.0213	CcSEcCtD
Saxagliptin—Nasopharyngitis—Vandetanib—thyroid cancer	0.00272	0.0204	CcSEcCtD
Saxagliptin—Gastritis—Vandetanib—thyroid cancer	0.00269	0.0202	CcSEcCtD
Saxagliptin—Opportunistic infection—Epirubicin—thyroid cancer	0.00259	0.0194	CcSEcCtD
Saxagliptin—Pancreatitis—Vandetanib—thyroid cancer	0.00258	0.0193	CcSEcCtD
Saxagliptin—DPP4—thyroid gland—thyroid cancer	0.00256	0.043	CbGeAlD
Saxagliptin—Upper respiratory tract infection—Vandetanib—thyroid cancer	0.00244	0.0183	CcSEcCtD
Saxagliptin—Opportunistic infection—Doxorubicin—thyroid cancer	0.0024	0.018	CcSEcCtD
Saxagliptin—Infestation NOS—Vandetanib—thyroid cancer	0.00235	0.0175	CcSEcCtD
Saxagliptin—Infestation—Vandetanib—thyroid cancer	0.00235	0.0175	CcSEcCtD
Saxagliptin—Urinary tract infection—Vandetanib—thyroid cancer	0.00228	0.0171	CcSEcCtD
Saxagliptin—DPP4—head—thyroid cancer	0.00227	0.0381	CbGeAlD
Saxagliptin—Sinusitis—Vandetanib—thyroid cancer	0.0022	0.0165	CcSEcCtD
Saxagliptin—Lymphopenia—Epirubicin—thyroid cancer	0.00204	0.0153	CcSEcCtD
Saxagliptin—Lymphopenia—Doxorubicin—thyroid cancer	0.00189	0.0141	CcSEcCtD
Saxagliptin—Nasopharyngitis—Sorafenib—thyroid cancer	0.00184	0.0137	CcSEcCtD
Saxagliptin—Malnutrition—Vandetanib—thyroid cancer	0.00183	0.0137	CcSEcCtD
Saxagliptin—ABCC1—trachea—thyroid cancer	0.00183	0.0307	CbGeAlD
Saxagliptin—Gastritis—Sorafenib—thyroid cancer	0.00182	0.0136	CcSEcCtD
Saxagliptin—Pancreatitis—Sorafenib—thyroid cancer	0.00174	0.013	CcSEcCtD
Saxagliptin—Erectile dysfunction—Sorafenib—thyroid cancer	0.00163	0.0122	CcSEcCtD
Saxagliptin—DPP4—lymph node—thyroid cancer	0.00159	0.0267	CbGeAlD
Saxagliptin—Infestation NOS—Sorafenib—thyroid cancer	0.00158	0.0118	CcSEcCtD
Saxagliptin—Infestation—Sorafenib—thyroid cancer	0.00158	0.0118	CcSEcCtD
Saxagliptin—Arthralgia—Vandetanib—thyroid cancer	0.00156	0.0117	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00155	0.0116	CcSEcCtD
Saxagliptin—SLC22A8—head—thyroid cancer	0.0015	0.0251	CbGeAlD
Saxagliptin—Infection—Vandetanib—thyroid cancer	0.00149	0.0111	CcSEcCtD
Saxagliptin—Thrombocytopenia—Vandetanib—thyroid cancer	0.00146	0.011	CcSEcCtD
Saxagliptin—Skin disorder—Vandetanib—thyroid cancer	0.00145	0.0109	CcSEcCtD
Saxagliptin—ABCC1—thyroid gland—thyroid cancer	0.00145	0.0243	CbGeAlD
Saxagliptin—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00136	0.0102	CcSEcCtD
Saxagliptin—Dyspepsia—Vandetanib—thyroid cancer	0.00132	0.00985	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00129	0.00966	CcSEcCtD
Saxagliptin—Fatigue—Vandetanib—thyroid cancer	0.00129	0.00965	CcSEcCtD
Saxagliptin—Immune system disorder—Sorafenib—thyroid cancer	0.00128	0.0096	CcSEcCtD
Saxagliptin—Malnutrition—Sorafenib—thyroid cancer	0.00124	0.00925	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00122	0.00915	CcSEcCtD
Saxagliptin—Abdominal pain—Vandetanib—thyroid cancer	0.00118	0.00885	CcSEcCtD
Saxagliptin—Angioedema—Sorafenib—thyroid cancer	0.00113	0.00845	CcSEcCtD
Saxagliptin—Asthenia—Vandetanib—thyroid cancer	0.00107	0.00803	CcSEcCtD
Saxagliptin—Pruritus—Vandetanib—thyroid cancer	0.00106	0.00792	CcSEcCtD
Saxagliptin—Myalgia—Sorafenib—thyroid cancer	0.00105	0.00788	CcSEcCtD
Saxagliptin—Arthralgia—Sorafenib—thyroid cancer	0.00105	0.00788	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00105	0.00782	CcSEcCtD
Saxagliptin—Anaphylactic shock—Sorafenib—thyroid cancer	0.00101	0.00755	CcSEcCtD
Saxagliptin—Infection—Sorafenib—thyroid cancer	0.001	0.0075	CcSEcCtD
Saxagliptin—Dizziness—Vandetanib—thyroid cancer	0.000989	0.0074	CcSEcCtD
Saxagliptin—Thrombocytopenia—Sorafenib—thyroid cancer	0.000988	0.00739	CcSEcCtD
Saxagliptin—Skin disorder—Sorafenib—thyroid cancer	0.00098	0.00733	CcSEcCtD
Saxagliptin—Vomiting—Vandetanib—thyroid cancer	0.000951	0.00712	CcSEcCtD
Saxagliptin—Rash—Vandetanib—thyroid cancer	0.000943	0.00706	CcSEcCtD
Saxagliptin—Dermatitis—Vandetanib—thyroid cancer	0.000942	0.00705	CcSEcCtD
Saxagliptin—Headache—Vandetanib—thyroid cancer	0.000937	0.00701	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.000919	0.00688	CcSEcCtD
Saxagliptin—ABCC1—lymph node—thyroid cancer	0.0009	0.0151	CbGeAlD
Saxagliptin—Nausea—Vandetanib—thyroid cancer	0.000888	0.00665	CcSEcCtD
Saxagliptin—Dyspepsia—Sorafenib—thyroid cancer	0.000888	0.00665	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000871	0.00652	CcSEcCtD
Saxagliptin—Fatigue—Sorafenib—thyroid cancer	0.00087	0.00651	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000825	0.00617	CcSEcCtD
Saxagliptin—Urticaria—Sorafenib—thyroid cancer	0.000802	0.006	CcSEcCtD
Saxagliptin—Abdominal pain—Sorafenib—thyroid cancer	0.000798	0.00597	CcSEcCtD
Saxagliptin—Purpura—Epirubicin—thyroid cancer	0.000787	0.00589	CcSEcCtD
Saxagliptin—Hypoglycaemia—Epirubicin—thyroid cancer	0.000777	0.00582	CcSEcCtD
Saxagliptin—Hypersensitivity—Sorafenib—thyroid cancer	0.000743	0.00556	CcSEcCtD
Saxagliptin—Face oedema—Epirubicin—thyroid cancer	0.000732	0.00548	CcSEcCtD
Saxagliptin—Purpura—Doxorubicin—thyroid cancer	0.000728	0.00545	CcSEcCtD
Saxagliptin—Asthenia—Sorafenib—thyroid cancer	0.000724	0.00542	CcSEcCtD
Saxagliptin—Hypoglycaemia—Doxorubicin—thyroid cancer	0.000719	0.00538	CcSEcCtD
Saxagliptin—Pruritus—Sorafenib—thyroid cancer	0.000714	0.00534	CcSEcCtD
Saxagliptin—Blood creatinine increased—Epirubicin—thyroid cancer	0.000711	0.00532	CcSEcCtD
Saxagliptin—Nasopharyngitis—Epirubicin—thyroid cancer	0.000678	0.00508	CcSEcCtD
Saxagliptin—Face oedema—Doxorubicin—thyroid cancer	0.000678	0.00507	CcSEcCtD
Saxagliptin—Gastritis—Epirubicin—thyroid cancer	0.000671	0.00502	CcSEcCtD
Saxagliptin—Dizziness—Sorafenib—thyroid cancer	0.000667	0.00499	CcSEcCtD
Saxagliptin—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000658	0.00492	CcSEcCtD
Saxagliptin—Pancreatitis—Epirubicin—thyroid cancer	0.000643	0.00481	CcSEcCtD
Saxagliptin—Vomiting—Sorafenib—thyroid cancer	0.000641	0.0048	CcSEcCtD
Saxagliptin—Rash—Sorafenib—thyroid cancer	0.000636	0.00476	CcSEcCtD
Saxagliptin—Dermatitis—Sorafenib—thyroid cancer	0.000636	0.00476	CcSEcCtD
Saxagliptin—Headache—Sorafenib—thyroid cancer	0.000632	0.00473	CcSEcCtD
Saxagliptin—Nasopharyngitis—Doxorubicin—thyroid cancer	0.000628	0.0047	CcSEcCtD
Saxagliptin—Gastritis—Doxorubicin—thyroid cancer	0.000621	0.00465	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000609	0.00456	CcSEcCtD
Saxagliptin—Nausea—Sorafenib—thyroid cancer	0.000599	0.00448	CcSEcCtD
Saxagliptin—Pancreatitis—Doxorubicin—thyroid cancer	0.000595	0.00445	CcSEcCtD
Saxagliptin—Infestation NOS—Epirubicin—thyroid cancer	0.000585	0.00437	CcSEcCtD
Saxagliptin—Infestation—Epirubicin—thyroid cancer	0.000585	0.00437	CcSEcCtD
Saxagliptin—Urinary tract infection—Epirubicin—thyroid cancer	0.000568	0.00425	CcSEcCtD
Saxagliptin—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000564	0.00422	CcSEcCtD
Saxagliptin—Sinusitis—Epirubicin—thyroid cancer	0.000548	0.0041	CcSEcCtD
Saxagliptin—Infestation NOS—Doxorubicin—thyroid cancer	0.000541	0.00405	CcSEcCtD
Saxagliptin—Infestation—Doxorubicin—thyroid cancer	0.000541	0.00405	CcSEcCtD
Saxagliptin—Urinary tract infection—Doxorubicin—thyroid cancer	0.000526	0.00393	CcSEcCtD
Saxagliptin—Oedema peripheral—Epirubicin—thyroid cancer	0.000517	0.00387	CcSEcCtD
Saxagliptin—Sinusitis—Doxorubicin—thyroid cancer	0.000508	0.0038	CcSEcCtD
Saxagliptin—Oedema peripheral—Doxorubicin—thyroid cancer	0.000478	0.00358	CcSEcCtD
Saxagliptin—Immune system disorder—Epirubicin—thyroid cancer	0.000474	0.00355	CcSEcCtD
Saxagliptin—Malnutrition—Epirubicin—thyroid cancer	0.000457	0.00342	CcSEcCtD
Saxagliptin—Flatulence—Epirubicin—thyroid cancer	0.00045	0.00337	CcSEcCtD
Saxagliptin—Immune system disorder—Doxorubicin—thyroid cancer	0.000439	0.00328	CcSEcCtD
Saxagliptin—Malnutrition—Doxorubicin—thyroid cancer	0.000423	0.00316	CcSEcCtD
Saxagliptin—Flatulence—Doxorubicin—thyroid cancer	0.000417	0.00312	CcSEcCtD
Saxagliptin—Arthralgia—Epirubicin—thyroid cancer	0.000389	0.00291	CcSEcCtD
Saxagliptin—Myalgia—Epirubicin—thyroid cancer	0.000389	0.00291	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000386	0.00289	CcSEcCtD
Saxagliptin—Anaphylactic shock—Epirubicin—thyroid cancer	0.000373	0.00279	CcSEcCtD
Saxagliptin—Infection—Epirubicin—thyroid cancer	0.00037	0.00277	CcSEcCtD
Saxagliptin—Thrombocytopenia—Epirubicin—thyroid cancer	0.000365	0.00273	CcSEcCtD
Saxagliptin—Skin disorder—Epirubicin—thyroid cancer	0.000362	0.00271	CcSEcCtD
Saxagliptin—Arthralgia—Doxorubicin—thyroid cancer	0.00036	0.00269	CcSEcCtD
Saxagliptin—Myalgia—Doxorubicin—thyroid cancer	0.00036	0.00269	CcSEcCtD
Saxagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000357	0.00267	CcSEcCtD
Saxagliptin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000345	0.00258	CcSEcCtD
Saxagliptin—Infection—Doxorubicin—thyroid cancer	0.000343	0.00256	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00034	0.00254	CcSEcCtD
Saxagliptin—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000338	0.00253	CcSEcCtD
Saxagliptin—Skin disorder—Doxorubicin—thyroid cancer	0.000335	0.00251	CcSEcCtD
Saxagliptin—Dyspepsia—Epirubicin—thyroid cancer	0.000328	0.00246	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000322	0.00241	CcSEcCtD
Saxagliptin—Fatigue—Epirubicin—thyroid cancer	0.000321	0.00241	CcSEcCtD
Saxagliptin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000314	0.00235	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000305	0.00228	CcSEcCtD
Saxagliptin—Dyspepsia—Doxorubicin—thyroid cancer	0.000304	0.00227	CcSEcCtD
Saxagliptin—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000298	0.00223	CcSEcCtD
Saxagliptin—Fatigue—Doxorubicin—thyroid cancer	0.000297	0.00223	CcSEcCtD
Saxagliptin—Urticaria—Epirubicin—thyroid cancer	0.000296	0.00222	CcSEcCtD
Saxagliptin—Abdominal pain—Epirubicin—thyroid cancer	0.000295	0.00221	CcSEcCtD
Saxagliptin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000282	0.00211	CcSEcCtD
Saxagliptin—Hypersensitivity—Epirubicin—thyroid cancer	0.000275	0.00206	CcSEcCtD
Saxagliptin—Urticaria—Doxorubicin—thyroid cancer	0.000274	0.00205	CcSEcCtD
Saxagliptin—Abdominal pain—Doxorubicin—thyroid cancer	0.000273	0.00204	CcSEcCtD
Saxagliptin—Asthenia—Epirubicin—thyroid cancer	0.000268	0.002	CcSEcCtD
Saxagliptin—Pruritus—Epirubicin—thyroid cancer	0.000264	0.00197	CcSEcCtD
Saxagliptin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000254	0.0019	CcSEcCtD
Saxagliptin—Asthenia—Doxorubicin—thyroid cancer	0.000248	0.00185	CcSEcCtD
Saxagliptin—Dizziness—Epirubicin—thyroid cancer	0.000247	0.00185	CcSEcCtD
Saxagliptin—Pruritus—Doxorubicin—thyroid cancer	0.000244	0.00183	CcSEcCtD
Saxagliptin—Vomiting—Epirubicin—thyroid cancer	0.000237	0.00177	CcSEcCtD
Saxagliptin—Rash—Epirubicin—thyroid cancer	0.000235	0.00176	CcSEcCtD
Saxagliptin—Dermatitis—Epirubicin—thyroid cancer	0.000235	0.00176	CcSEcCtD
Saxagliptin—Headache—Epirubicin—thyroid cancer	0.000234	0.00175	CcSEcCtD
Saxagliptin—Dizziness—Doxorubicin—thyroid cancer	0.000228	0.00171	CcSEcCtD
Saxagliptin—Nausea—Epirubicin—thyroid cancer	0.000221	0.00166	CcSEcCtD
Saxagliptin—Vomiting—Doxorubicin—thyroid cancer	0.000219	0.00164	CcSEcCtD
Saxagliptin—Rash—Doxorubicin—thyroid cancer	0.000218	0.00163	CcSEcCtD
Saxagliptin—Dermatitis—Doxorubicin—thyroid cancer	0.000217	0.00163	CcSEcCtD
Saxagliptin—Headache—Doxorubicin—thyroid cancer	0.000216	0.00162	CcSEcCtD
Saxagliptin—Nausea—Doxorubicin—thyroid cancer	0.000205	0.00153	CcSEcCtD
